Buy Jubilant Ingrevia, target price Rs 592: IIFL Securities
IIFL Securities has initiated a 'buy' call on Jubilant Ingrevia, with a target price of Rs 592, representing a potential upside of 4.6%. The brokerage firm believes that the company's strong earnings growth, driven by volume growth and margin expansion, will continue in the coming quarters. Jubilant Ingrevia is a leading life sciences company with a global presence. The company has a strong product portfolio in the specialty chemicals and pharmaceuticals segments.
About Jubilant Ingrevia:
Jubilant Ingrevia Limited, a global company headquartered in India, is a leading manufacturer of specialty chemicals and nutritional products. Its Specialty Chemicals division focuses on life science ingredients, pharmaceutical intermediates, and performance polymers. The Nutrition & Health division produces and markets specialty micronutrients, probiotics, enzymes, and other health ingredients. The company has manufacturing facilities in India, the Netherlands, Canada, and the United States, and its products are sold in over 90 countries. Jubilant Ingrevia is committed to innovation, sustainability, and customer satisfaction, and has been recognized for its excellence in these areas.
52 Week Price Trend:
Jubilant Ingrevia (NSE: JUBLINGREA) is currently trading at Rs 566, within a range of Rs 350.45 to Rs 524.7 over the past year. The stock has witnessed a significant rise from its 52-week low, indicating positive market sentiment. However, it is still below its 52-week high, suggesting some room for further growth. Investors may consider the current price point as a potential entry opportunity, but it is crucial to conduct thorough research and analysis before making any investment decisions.
Stratzy's MOST Analysis:
JUBLINGREA has been assigned a BB- rating by Stratzy's MOST framework, indicating medium fundamental risks. This assessment is derived from an evaluation of the company's Management, Outlook, Safety, and Trend (MOST) pillars. While JUBLINGREA may have some strengths in these areas, the BB- rating suggests that there are also areas of concern that investors should consider before making investment decisions.
Company's Fundamentals:
Jubilant Ingrevia (NSE: JUBLINGREA) is a specialty chemicals company engaged in the manufacture of pyridine, nicotinamide, and other derivatives. Its stock has a trailing price-to-earnings (PE) ratio of 37.66, indicating that investors are willing to pay a premium for each rupee of earnings. The price-to-book (PB) ratio of 2.87 implies that the market value of the company's assets is 2.87 times their book value. Jubilant Ingrevia offers a dividend yield of 1.03%, providing shareholders with a modest income stream.
Fundamental and Technical information provided in this blog were last updated on 09 Jul, 2024
Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.